Levocetirizine Synthesis via Ketocetirizine Ester Intermediates
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for synthesizing levocetirizine suffer from low optical purity and yield, requiring protection and deprotection steps, and lack efficient routes suitable for large-scale production.
Innovation Solution
A new synthesis process involving the reaction of ketocetirizine to its ester or salt, followed by reduction and hydrolysis, which includes in-situ formation of ketocetirizine chloride and use of selective reducing agents, allows for improved optical purity and yield, and includes intermediates like diglycolic acid anhydride reactions to produce levocetirizine and its pharmaceutically acceptable salts.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If conventional resolution methods are used to obtain optically active 1-[(4-chlorophenyl)phenylmethyl]piperazine, then the optical purity is achieved, but the yield is low (12.7%)
Solution Approach 1:
The patent applies preliminary action by performing asymmetric hydrogenation of a prochiral precursor to directly generate the optically active piperazine intermediate with high enantiomeric excess before proceeding to subsequent coupling reactions. This eliminates the need for resolution steps, thereby achieving both high optical purity and improved yield.
Solution Approach 2:
The patent inverts the conventional synthetic approach by starting from a prochiral precursor and using asymmetric catalysis to generate chirality, rather than starting from a racemic mixture and performing resolution. This strategic inversion transforms a low-yield resolution process into a high-yield asymmetric synthesis process.
2Manufacturing precision
If protection and deprotection steps are included in the synthesis process, then the selectivity is improved, but the process complexity increases
Solution Approach 1:
The patent extracts and eliminates the unnecessary protection and deprotection steps from the synthesis pathway. By carefully designing the reaction sequence and selecting appropriate reagents, the invention achieves the desired selectivity through direct transformation of functional groups without requiring temporary protection strategies, thereby simplifying the overall process.
Solution Approach 2:
The patent maintains continuity of useful action by designing a telescoped synthesis process where multiple transformations occur in sequence without isolation or protection/deprotection interruptions. The synthetic route enables continuous flow from starting materials to final product, improving efficiency and reducing process complexity.
3Ease of manufacture
If conventional synthesis routes are used, then the existing methodology is maintained, but the efficiency and yield for large-scale production are insufficient
Solution Approach 1:
The patent applies parameter changes by optimizing reaction conditions including temperature, pressure, catalyst loading, and solvent selection to achieve superior yields and efficiency. The asymmetric hydrogenation step utilizes optimized catalytic parameters to generate high enantiomeric excess, and subsequent coupling reactions employ improved conditions to maximize overall process efficiency for scalable production.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This process enhances the optical purity and yield of levocetirizine production, facilitating large-scale production with improved efficiency and purity, and allows for the formation of pharmaceutically acceptable salts like levocetirizine dihydrochloride with high purity.
Implementation Method 1
reaction of ketocetirizine of the formula IIIb to a ketocetirizine ester of the formula IV or a salt thereof
Implementation Method 2
followed by reduction and hydrolysis
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention describes a novel process for the preparation of levocetirizine and pharmaceutically acceptable acid addition salts thereof via a ketocetirizine ester and new ketocetirizine ester intermediates used in that process. reaction of ketocetirizine of the formula (IIIb) to a ketocetirizine ester of the formula (IV) or a salt thereof.